GPCR targets are central to next-generation therapies for obesity and type 2 diabetes, but translating their potential into successful drug candidates requires more predictive and integrated evaluation strategies. This whitepaper introduces a comprehensive in-vitro screening platform that brings together diverse assay technologies into a unified workflow, enabling deeper insight into compound behavior and more informed decision-making across early discovery. By improving the quality and efficiency of GPCR-targeted research, this approach helps accelerate the path toward clinically relevant metabolic therapies.

• Integrated platform design: Combines multiple in-vitro assay technologies into a unified workflow for streamlined GPCR profiling
• Comprehensive target coverage: Enables evaluation across key receptors including GLP-1R, GIPR, GCGR, Amylin, APJ, GPR75, and MC4R
• Multi-dimensional functional insights: Captures activity, selectivity, and signaling pathways to support better candidate differentiation
• Improved decision-making: Generates robust, comparable data to reduce uncertainty and guide early-stage discovery

Download the full whitepaper to discover how integrated screening strategies can help bring next-generation metabolic therapies closer to reality.